A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

Study Summary

This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.

Conditions

Major Depressive Disorder

Interventions / Drugs

AXS-05 Bupropion

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment350 participants

Primary Completion—

Lead SponsorAxsome Therapeutics, Inc.

Data Retrieved2026-04-11 04:06:36.562767+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.